23 Jan Autolus Therapeutics
Posted at 17:13h
in
Christopher Vann, Chief Operating Officer
April 15 | 12:00pm | Salone dei Cavalieri, Section 2
London, United Kingdom
(NASDAQ GS: AUTL)
Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases.
